[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adhd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adhd":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,82,0,25,[9,45,72,97,184,222,251,288,319,338,366,396,416,449,474,504,533,559,589,615,646,675,704,722,746],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100636498","role-of-theta-frequency-oscillations-in-proactive-and-reactive-control-processes-in-youth-with-attention-deficit-hyperactivity-disorder-adhd-and-obsessive-compulsive-disorder-ocd-100636498",false,"NCT07566468","Role of Theta Frequency Oscillations in Proactive and Reactive Control Processes in Youth With Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive Compulsive Disorder (OCD)","* INCLUSION CRITERIA:\n\n  1. Ability to provide informed assent and parent consent\n  2. Age: 10-17 years\n  3. ADHD Group: Diagnosis of ADHD based on DSM-5 criteria\n\n     OCD Group: Diagnosis of OCD based on DSM-5 criteria\n\n     HV Group: No Neurological or Psychiatric diagnosis based on DSM-5 criteria\n  4. Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-II). WASI-II will be used as a measure of intellectual function. Children will be included when FSIQ \\> 70.\n  5. Normal or corrected to normal vision\n\nEXCLUSION CRITERIA:\n\nParticipants will be screened to exclude participants in whom MRI or EEG might result in increased risk of side effects or complications or whose data would not be scientifically valid.\n\n1. Non-English Speakers\n2. Pregnancy\n3. Any implant, prosthesis or alteration of the body that, in the opinion of the investigator, would be unsafe with MRI or EEG or that would produce an artifact that would compromise the integrity of data;\n4. Active or History of psychosis, bipolar I disorder, Level 2 or 3 autism spectrum disorder, active severe substance use disorders (within the last month), have active suicidal intent or plan as detected on screening instruments;\n5. Individuals currently taking stimulant medications who cannot tolerate being off their medication for up to 48 hours prior to the study visit and experience an exacerbation of symptoms that necessitates the resumption of medication prior to completion of the study visit.\n6. Past or present medical or neurological condition, disease, disorder, genetic finding, or injury that, in the opinion of the Investigator, may significantly increase the potential risks of study participation, reduce or compromise a subject s ability to fully comply with all study requirements for the duration of the study or may compromise the integrity of the data.\n7. For the HV group, any impairing current psychiatric diagnosis.","ALL","10 Years","17 Years",{"count":20,"type":21},110,"ESTIMATED","OBSERVATIONAL","Background:\n\nAttention deficit hyperactivity disorder (ADHD) is common in children. It can cause problems with attention and the ability to control actions and impulses. Obsessive compulsive disorder (OCD) is less common in children but not rare. It involves ongoing thoughts, urges, impulses, and repeated behaviors. Researchers want to study differences in brain activity between healthy children, those with ADHD, and those with OCD.\n\nObjective:\n\nTo learn more about how the brain controls thinking and behavior.\n\nEligibility:\n\nPeople aged 10 to 17 years with ADHD, OCD, or neither.\n\nDesign:\n\nParticipants will have 3 to 10 clinic visits in up to 1 year. Each visit will last 2 to 3 hours.\n\nThree visits are required:\n\nBehavioral. Participants will complete a computer task. Their mood, memory, attention, and thinking skills will be tested.\n\nEEG. Participants will undergo electroencephalography (EEG) to measure signals in their brain. Small electrodes will be placed on the scalp. A cap will be stretched over the head. Signals will be recorded while participants rest or do tasks on a computer.\n\nMRI. Participants will have a magnetic resonance imaging scan (MRI). They will lie on a table that rolls into a tube. The MRI will take pictures of their brain while they do tasks on a computer.\n\nSeven more visits are optional. These include 2 more EEG visits and 2 more MRI visits.\n\nThree will be magnetoencephalography (MEG) visits: MEG measures small magnetic field changes in the brain. A helmet with sensors will be placed on the head. Brain changes will be recorded while participants rest or do tasks on a computer.",[25,26,27],"ADHD","Obsessive Compulsive Disorder (OCD)","Healthy Volunteer",[29,30,31],"EEG","MRI","fMRI","NOT_YET_RECRUITING","2026-08-20",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":21},"2026-08-26",{"date":40,"type":21},"2029-05-31",{"name":42,"class":43},"National Institute of Mental Health (NIMH)","NIH",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":16,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100646968","impact-of-short-and-mistimed-sleep-on-adolescents-with-adhd-the-adolescent-attention-and-circadian-timing-study-100646968","NCT07684417","Impact of Short and Mistimed Sleep on Adolescents With ADHD: The Adolescent Attention and Circadian Timing Study","Impact of Circadian Misalignment for Adolescents With ADHD: Observational and Mechanistic Data","AACT","Inclusion Criteria:\n\n* Ages 13-17 years at time of informed consent\u002Fassent\n* Based on semi-structured clinical interview, participants must meet full DSM-5 criteria for ADHD inattentive or ADHD combined presentation.\n\nExclusion Criteria:\n\n* Non-traditional school setting (morning-afternoon Monday-Friday).\n* Exclusionary diagnoses. We will exclude adolescents with known intellectual disability, autism spectrum disorder, psychosis, bipolar disorder, or neurologic conditions (e.g., epilepsy), per caregiver-report.\n* Exclusionary sleep disorders. We will exclude adolescents with symptoms of obstructive sleep apnea or periodic limb movement disorder based on published cutoffs on a validated questionnaire.\n* High caffeine intake. To promote adherence to directives not to consume caffeine the day of office visits without withdrawal effects, adolescents with daily intake of \\>1 coffee or \"energy drink\" or \\>2 caffeinated sodas per day based on caregiver- and adolescent-report will be excluded.\n\n  * Unwillingness or inability to take part in study procedures (e.g., visits, prescribed sleep conditions).\n  * Medication use or unwillingness to discontinue melatonin and\u002For stimulant medications during the 3-week study protocol.\n* Refusal to refrain from automobile driving during the sleep restriction condition.\n* \"Intermediate\" Chronotypes (neither morning larks nor night owls) based on habitual sleep timing on nights when adolescent has no morning obligations such as school or work.","13 Years",{"count":55,"type":21},50,"INTERVENTIONAL",[58],"NA","Many adolescents go to bed late and wake up early for school. Science is only beginning to understand how sleep schedules can affect them. The investigators are interested in whether changing adolescents' sleep patterns affects their functioning, attention, and how they feel. The investigators are especially interested in the effects of changing both how much sleep adolescents get and when that sleep happens.\n\nThis study focuses on healthy 13-17-year-olds with ADHD. This study asks adolescents to systematically change their sleeping habits across a 3 week span. The first week, they follow a sleep schedule that fits reasonably well with the schedule they keep when they do not have to wake up early for any specific obligation (e.g., for school). The second week, they spend several nights in a \"short sleep\" condition, during which they get 6.5 hours in bed per night. The final week, they enter a sleep condition that allows for healthy sleep duration, but with a timing that is randomly assigned to either fit well with their preferred schedule or fit poorly with that schedule. During each week, they and their parents complete measures of their attention and other factors. At the end of each week, they attend an evening session to measure their internal body clock (\"circadian phase\"), as well as measures of attention and other thinking skills. The goal is to understand whether the benefits of healthy sleep duration depend on the timing of when that sleep occurs.",[25],"RECRUITING","2026-08-13",{"date":64,"type":36},"2026-08-17",{"date":66,"type":36},"2026-07-10",{"date":68,"type":21},"2030-08",{"name":70,"class":71},"Children's Hospital Medical Center, Cincinnati","OTHER",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":56,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100652021","efficacy-of-cognitive-behavioural-therapy-for-insomnia-and-bright-light-therapy-in-adolescents-with-adhd-insomnia-and-evening-chronotype-100652021","NCT07767617","Efficacy of Cognitive Behavioural Therapy for Insomnia and Bright Light Therapy in Adolescents With ADHD, Insomnia, and Evening Chronotype","Efficacy of Cognitive Behavioural Therapy for Insomnia and Bright Light Therapy in Adolescents With ADHD and Comorbid Insomnia and Evening Chronotype: A Randomised, Assessor Blind, Parallel-group Trial","Inclusion criteria:\n\nAn adolescent who meets the following criteria will be eligible for taking part in this study:\n\n1. aged 10-24 years old;\n2. ADHD diagnosis confirmed by DISC-IV;\n3. DSM-5 diagnosis of insomnia disorder with an ≥ 9 (suggested cut-off for adolescents);\n4. Being classified as evening chronotype according to the score on the Horne-Östberg Morning-Eveningness Questionnaire (MEQ) and having a sleep onset time of 11:15pm or later for 12 year olds, 11:30pm or later for 13-14 year olds, 12:00am or later for 15-17 years old \\[64\\], 10:56pm or later for 18-24 years old at least 3 nights per week in the past 3 months and as confirmed by a 7-day sleep diary;\n5. Written informed consent from the participant and their parent\u002Fguardian (for those aged under 18);\n6. Being able to comply with the study protocol;\n7. Either not on ADHD medication or stabilized on medications for at least 6 months.\n\nExclusion criteria:\n\nAn adolescent who meets one or more of the following criteria will be excluded from the study:\n\n1. Substance abuse or dependence; a current or past history of manic or hypomanic episode, schizophrenia, ASD, organic mental disorders, or intellectual disabilities;\n2. Prominent medical condition affecting sleep (e.g., severe eczema, GERD);\n3. Clinically diagnosed sleep disorder other than insomnia disorder, such as narcolepsy, sleep-disordered breathing, and restless leg syndrome;\n4. Concurrent, regular use of medications(s) known to affect sleep continuity and quality including both prescribed medications (e.g., hypnotics, steroids) and over-the-counter OTC medications (e.g., melatonin, Traditional Chinese Medicine, TCM), except for ADHD stimulants;\n5. Ongoing psychological treatment for sleep problems;\n6. With hearing or speech deficit;\n7. Having a clinically significant suicidality (presence of suicidal ideation with a plan or an attempt).","24 Years",{"count":81,"type":21},150,[58],"Attention-deficit\u002Fhyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by persistent inattention, hyperactivity, and impulsivity. In adolescents and young people, ADHD is commonly accompanied by insomnia and circadian delay. These co-occurring sleep and circadian disturbances may negatively affect daytime functioning and overall clinical outcomes. Although cognitive behavioural therapy for insomnia (CBT-I) is considered the first-line treatment for insomnia, and bright light therapy may help address circadian issues, their efficacy in adolescents with ADHD and comorbid insomnia and eveningness remains unexplored. This study aims to evaluate whether CBT-I, with or without bright light therapy, improves insomnia, sleep, and circadian as well as other clinical outcomes, and cognitive functioning in youths with ADHD and whether these interventions can also lead to improvements in mood and other clinical symptoms, as well as cognitive functioning.",[85,25,86,87,88],"Insomnia","Eveningness","Chronotype","Treatment Effectiveness","2026-08-11",{"date":64,"type":36},{"date":92,"type":21},"2026-08-10",{"date":94,"type":21},"2029-08-31",{"name":96,"class":71},"The University of Hong Kong",{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":16,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":56,"phases":109,"briefSummary":110,"conditions":111,"keywords":155,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":44},"100641475","qaiax-aihealth4u---ai-public-health-central-microcity-a-re-quantum-ai-agency-aka-ai-city-hall-project-upsto-app-nos-64074526-64063557-63903181-63729428-100641475","NCT07661823","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App No(s). 64\u002F105,164, 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428: A Quantum AI Public Health Agency That Provides Free Public Health Services to Registered and Sponsored Visitors\u002FOccupants for RDT&E Under 28 U.S. Code 1498 (Classified as a PPA Under 10 U.S. Code 129a)","QAIAx","Inclusion Criteria:\n\n* Individuals aged 17 to 99 years old.\n* Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).\n* Referral by a non-profit organization (e.g., 501c3, university, church).\n* Referral by a public agency (e.g., case manager, social worker, parole\u002Fprobation\u002FPTS officer, judge).\n\nExclusion Criteria:\n\n\\* Individuals under 17 or over 99 years of age.",true,"99 Years",{"count":108,"type":21},1000000,[58],"BRIEF SUMMARY\n\nA. \"What is the purpose of this study?\"\n\nThis study will test whether the \"AI City Hall Project\" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called \"Microcities\". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.\n\nB. \"What conditions does the study focus on?\"\n\nThe study focuses on adults with:\n\n* Autism spectrum disorders (Asperger's, autism, ADHD, ASD)\n* Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA\u002Fecstasy, tobacco\u002Fnicotine)\n* Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders)\n* Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).\n\nC. \"What does the study involve?\"\n\nEligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital \"attitude inoculation\" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.\n\n\\*\\*Who can participate?\\*\\*\n\nYou may be able to join if you:\n\n* Are an adult (18 years or older)\n* Have a diagnosis of one of the listed mental-health or addiction disorders\n* Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organisation (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole\u002Fprobation officer, judge)\n* Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.\n\nParticipants who are veterans, receive public assistance (e.g., VA disability, SSDI\u002FSSI, Medicaid, Medicare), or are experiencing homelessness may be prioritised.\n\n\\*\\*Where is the study taking place?\\*\\* The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.\n\n\\*\\*Who is sponsoring the study?\\*\\* The study is sponsored by \\*\\*Veterans Recovery Network Inc.\\*\\*, a non-profit organization, in collaboration with \\*\\*AI-119 Vulcan Project Research \\& Educational Technology Co. (PRETCO)\\*\\* and an AI legal agency. The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §129a) and is part of a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM).\n\nThis summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.",[112,113,114,115,116,25,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154],"Asperger's Disorder","Asperger Disorder","Autism Disorder","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","ASD","Alcohol Abuse\u002FDependence","Alcohol Addiction","Alcohol and Other Drug Use Disorders","Alcohol and Other Substance Use Prevention","Gambling Addiction","Gambling Disorder","Sex Abuse","Sex Behavior","Sex Crimes","Sex Disorder","Sex Disorders","Gender Dysphoria, Adult","Eating Behavior Disorders","Narcotic-Related Disorders","Narcotic Addiction","Narcissism","Psychiatric Disorder","Psychedelic Effects in Healthy Volunteers","Psychedelic Experiences","Psychedelic Drug Dependence","Marijuana Use Disorder","Marijuana Abuse and Dependence","Smoking (Tobacco) Addiction","Smoking Among Youth","Smoking Abstinence","Abstinence, Sex","Opiate Substitution Treatment","Opioid Abuse (Disorder)","Opioid Abuse and Addiction","Cocaine Abuse","MDMA ('Ecstasy')","Addiction Disorders","Homeless and Low Incomes People, Refugees","Homelessness","Reliability and Validity","Anger Problems","Child Abuse, Sexual",[156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175],"ai city hall project","ai 119","ai119","qaia","qaiax","ai wat","veterans recovery network","veterans","addiction disorder","vulcan","artificial intelligence","agi","military","sex addiction","mental health treatment","smart health cities","microcities","smartcities","smart city","omni ai",{"date":177,"type":36},"2026-08-12",{"date":179,"type":21},"2026-08-01",{"date":181,"type":21},"2028-12-31",{"name":183,"class":71},"Veterans Recovery Network Inc.",{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":105,"sex":16,"minAge":53,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":56,"phases":195,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":44},"100650932","a-clinical-trial-evaluating-fecal-microbiota-transplantation-fmt-in-adolescents-with-adhd-100650932","NCT07756255","A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD","Feasibility, Safety and Tolerability of Fecal Microbiota Transplantation in an Adolescent Population With Attention Deficit Hyperactivity Disorder (ADHD)","FMT-ADHD-2026","Inclusion Criteria:\n\n1. Between 13-17 years of age with consent of a legal guardian: Participants should be at least 13 years old and not older than 17 years at the day of screening (V1).\n2. Have a primary diagnosis of ADHD as confirmed by the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).\n3. Be on a stable appropriate dose of an appropriate first-line pharmacological treatment for at least 8 weeks prior to the day of screening (V1).\n\n   a. First line pharmacotherapy treatment will be defined based on the CADDRA guidelines \\[63\\] and include the following\n\n   Amphetamine-based psychostimulants:\n\n   i. Mixed amphetamine salts (amphetamine and dextroamphetamine) ii. Lisdexamfetamine dimesylate\n\n   Methylphenidate-based psychostimulants:\n\n   i. Methylphenidate hydrochloride, Methylphenidate hydrochloride (extended release, multilayer release capsules) ii. Methylphenidate hydrochloride (extended release, OROS tablets) iii. Methylphenidate hydrochloride (controlled release, multi-layer beat capsules) iv. Methylphenidate hydrochloride (extended-release oral suspension)\n4. Have a score of ≥ 18 on the inattention subset (questions 1-9) and\u002For the hyperactivity\u002Fimpulsivity subset (questions 10-18) of the SNAP-IV 26-Item Parent Rating Scale on the day of screening (V1) and the baseline visit (V2).\n5. Able to communicate and complete study assessments in English.\n6. Able to comply with all protocol procedures.\n7. Consenting guardian\n\nExclusion Criteria:\n\n1. Participant meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Criteria for the following conditions according to the MINI-KID:\n\n   1. Diagnosis of a Substance Use Disorder within the last 3 months prior to screening. \\*(Criteria should include Alcohol and Non-Alcohol substances except Cannabis)\n   2. Moderate or severe Substance Use Disorder for Cannabis use in the last 3 months\n   3. Currently active high suicidality. Eligibility of Participants who meet criteria for moderate suicidality is determined by clinical judgment of Principal Investigator.\n   4. Active Anorexia Nervosa or Bulimia Nervosa in the last 3 months.\n   5. Tic Disorders\n   6. Psychosis\n   7. Obsessive Compulsive Disorder\n   8. Bipolar Disorder\n   9. Conduct Disorder\n2. Participant has a score of ≥ 8 on the oppositional defiant subset of the SNAP-IV 26-Item Parent Rating Scale (questions 19-26) on the day of screening (V1).\n3. Intellectual or learning disability based on previous documented diagnosis or clinical judgment of Principal Investigator.\n4. Documented diagnosis of Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) or Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS).\n5. Documented diagnosis of schizophrenia or schizoaffective disorder.\n6. Documented diagnosis of Autism Spectrum Disorder (ASD) or currently undergoing assessment for suspected ASD.\n7. Use of systemic antibiotics for medical purposes within the last 3 months prior to the day of screening (V1).\n8. Use of prebiotics or probiotics for medical purposes for more than 2 weeks within the last 3 months prior to the day of screening (V1).\n\n   a) Eligibility and required washout period of participants with use of over-the-counter prebiotics or probiotics will be determined by clinical judgment of Principal Investigator.\n9. Use of experimental drugs in the last 3 months prior to the day of screening (V1).\n10. Documented clinical diagnosis of inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, and\u002For celiac disease.\n11. Documented diagnosis of conditions causing immunosuppression and\u002For currently receiving immunosuppressive treatments.\n12. Documented clinical diagnosis of significant bleeding disorders.\n13. History of oropharyngeal dysphagia or other swallowing disorder, and\u002For self or study partner reported difficulty with taking oral capsules or pills.\n14. Breastfeeding, pregnant or seeking to get pregnant during the course of this study. Female participants of childbearing age should be using an acceptable method of birth control (implants, injectable, combined oral contraceptives, IUDs, barrier contraceptives, sexual abstinence, or a vasectomized partner) for the duration of their participation in the trial.\n15. Participants who are currently hospitalized or institutionalized.\n16. Reported allergy to Vancomycin or Nitazoxanide\n17. Hepatic dysfunction:\n\nA) Documented history or current diagnosis of an acute or chronic hepatic disease (e.g., cirrhosis, hepatitis, hepatic impairment) OR\n\nB) Abnormal - Liver Function Tests (LFTs): Screening laboratory results indicating clinically significant hepatic dysfunction:\n\n* Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥3 the Upper Normal Limit (UNL)\n* Total Bilirubin \\> 1.5 × ULN (except in cases of documented Gilbert's Syndrome) 19. Renal dysfunction: A) Diagnosed Renal Disease: Any documented medical history or current diagnosis of kidney disease, acute kidney injury, or other clinically significant renal impairment. OR B) Abnormal Renal Function Tests: Screening laboratory results indicating significant renal dysfunction. Creatinine \\> 1.5 × ULN\\*\n\n  * Potential participants presenting with mild, non-clinically significant laboratory abnormalities (e.g., AST\u002FALT between 1.0 and 3.0 × ULN, or isolated borderline creatinine variations confirmation of enrollment into the study will be dependent of the study physician.","18 Years",{"count":194,"type":21},64,[196],"PHASE2","The primary goals of this phase 2 clinical trial are to determine the feasibility, safety, and tolerability of oral Fecal Microbiota Transplantation (FMT) in adolescents (aged 13-17) with Attention-Deficit\u002FHyperactivity Disorder (ADHD).",[25,116,199],"ADHD - Combined Type",[201,202,203,204,205,206,207,208,25,209,210,211,212,213,214],"microbiome","microbiota transplants","fecal microbiota transplantation","gut microbiome therapy","gut microbiome","gut microbiota","neurodevelopmental disorders","neurodevelopment","Attention Deficit Hyperactivity Disorder","gut brain axis","FMT","adolescent psychiatry","psychiatry","neuroscience","2026-08-05",{"date":92,"type":36},{"date":218,"type":21},"2026-08-31",{"date":94,"type":21},{"name":221,"class":71},"University of Calgary",{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":16,"minAge":230,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":56,"phases":233,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":44},"100302753","virtual-reality-attention-management-100302753","NCT03221244","Virtual Reality Attention Management","Virtual Reality Attention Management Program for Improving Attention in Children","VRAM","Inclusion Criteria:\n\n* Significant (T score \\>= 60) ratings of Cognitive Problems\u002FInattention or DSM Inattention scale scores on the Conners' Parent or Teacher Rating Scale-3 or Parent ADHD Rating Scale-IV (ADHD-RS)\n* Endorsement of 4 or more symptoms of inattention on a clinical psychiatric interview (e.g. Parent DISC, DICA, Kiddie-SADS, Mini-KID)\n* Comfortable using a computer\n* Full Scale IQ \\> 80\n\nExclusion Criteria:\n\n* Psychosis (by parent report at phone screen), significant depression, autism (15 or \\> on Social Communication Questionnaire (SCQ)), psychotic disorders, visual or hearing impairment or any other disorder that may interfere with task performance\n* It is in the investigator's opinion that it is not in the subject's best interest to continue\n* Subject is non-compliant with training schedule\n* Subjects on pharmacotherapy for ADHD at the time of enrollment will be excluded from Aims 3 and 4.\n* Subjects starting behavioral or psychological treatment for ADHD during the training phase of the study will be excluded","8 Years","12 Years",{"count":55,"type":21},[58],"Problems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects. For example, susceptibility to distraction is associated with worse school and social performance, lower high school graduation rates, and increased incidence of serious accidents. The investigators' goal is to improve understanding of distractibility and develop a targeted treatment. The proposed intervention is based on models of habituation, which is a term that means reduced physiological and emotional response to a stimulus (e.g. moving object, or loud noise, etc.) as it is seen repeatedly. The investigators use virtual reality technology to show study participants distracting stimuli repeatedly in a virtual classroom setting, and their hypothesis states that participants will improve attention in the face of distraction by training with this technology intervention. The virtual classroom setting is especially relevant for children who have significant challenges with distractibility, such as children with ADHD. This intervention will likely be effective in helping individuals with other clinical disorders and perhaps the general population as well.",[25],[237,238,239,240,241],"Distractibility","Virtual Reality","Attention","Child","Pediatric","2026-08-04",{"date":244,"type":36},"2026-08-07",{"date":246,"type":36},"2016-06-02",{"date":248,"type":21},"2027-07-02",{"name":250,"class":71},"University of California, Davis",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":16,"minAge":230,"maxAge":18,"enrollmentInfo":259,"targetDuration":4,"studyType":56,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100522340","phase-2-sertraline-vs-placebo-in-the-treatment-of-anxiety-in-children-and-adolescents-with-neurodevelopmental-disorders-100522340","NCT06081348","Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","CALM","Inclusion Criteria:\n\n1. Outpatients 8-17 years of age, inclusive\n2. Females of child bearing potential who are sexually active and agree to use medically acceptable birth control throughout the study and at least one week post last dose of study drug.\n3. Meet Diagnostic and Statistical Manual of Mental Disorders - DSM-5 criteria for ASD, ADHD, Tic Disorders, or genetic diagnosis of Fragile X, tuberous sclerosis or 22q11 deletions.\n4. Meet DSM-5 criteria for one of the following anxiety disorders: Separation Anxiety Disorder, Social Anxiety Disorder, Agoraphobia, Generalized Anxiety Disorder, or Unspecified Anxiety Disorder, based on expert clinical interview, supported by the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS; Kaufman et al., 2016). Other specified anxiety disorder is included to account for youth with impairing anxiety symptoms who may not meet criteria for one of the other anxiety disorders.\n5. Have a Clinician's Global Impression-Severity for anxiety (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill) (inter-rater reliability will be done prior to initiation of enrollment, using videotapes of interviews and vignettes)\n6. If already receiving interventions, must meet the following criteria:\n\n   1. If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening and will not electively modify ongoing medications for study duration\n   2. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions\n7. Ability to complete assessments in English\n\nExclusion Criteria:\n\n1. Receiving other SSRIs within four weeks of randomization (6 weeks for fluoxetine)\n2. Previous treatment with sertraline, at an adequate dose (at least 100mg for 6 weeks, or lower dose and duration if not well-tolerated), associated with no response or significant-to-the-participant side effects.\n3. Received more than 2 previous appropriate trials of SSRIs with no adequate response\n4. Pregnant females or sexually active females on inadequate contraception\n5. Serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger participant. In addition diabetic patients on medications for glycemic control will be excluded as sertraline may interfere with glycemic control.\n6. Hypersensitivity to sertraline or any components of its formulation\n7. On Monoamine Oxidase Inhibitors or pimozide (as per product monograph)\n8. On concomitant medications known to significantly increase QT interval where this would result in unacceptable risk per Investigator judgment.\n9. Known congenital QT prolongation\n10. HIV, hepatitis B or C, hemophilia, abnormal blood pressure, substance abuse, immunity disorder, major depressive episode or psychosis (as required by Health Canada)\n11. Unable to tolerate venipuncture\n12. Unable to swallow capsules\n13. Enrolled in another intervention study",{"count":260,"type":21},130,[196],"There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.",[264,115,265,266,267,268,269,25,270,271,272,273,199,274,275,276,277],"Neurodevelopmental Disorders","Autism Spectrum Disorder","Fragile X Syndrome","Tuberous Sclerosis","22Q11 Deletion Syndrome","22Q11 Deletion","Tic Disorders","Tourette Syndrome","Tourette Syndrome in Children","Tourette Syndrome in Adolescence","ADHD Predominantly Inattentive Type","ADHD, Predominantly Hyperactive - Impulsive","Anxiety","Anxiety Disorders","2026-07-24",{"date":280,"type":36},"2026-07-27",{"date":282,"type":36},"2024-09-16",{"date":284,"type":21},"2027-09",{"name":286,"class":71},"Holland Bloorview Kids Rehabilitation Hospital",7,{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":16,"minAge":231,"maxAge":18,"enrollmentInfo":295,"targetDuration":4,"studyType":56,"phases":297,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":318},"100648128","phase-3-a-study-to-assess-the-efficacy-and-safety-of-solriamfetol-in-adolescents-with-adhd-100648128","NCT07717892","A Study to Assess the Efficacy and Safety of Solriamfetol in Adolescents With ADHD","A Phase 3, Randomized, 6-Week, Double-blind, Placebo- Controlled Trial of Solriamfetol in Adolescents Aged 12 to \u003C18 Years With Attention Deficit Hyperactivity Disorder (ADHD)","Inclusion Criteria:\n\n* Male or female, aged 12 to \\\u003C18 years.\n* Primary diagnosis of ADHD according to DSM-5 criteria.\n* Has parents\u002Flegal guardians provide written informed consent and has child provide written informed assent to participate in the study before the conduct of any study procedures.\n\nExclusion Criteria:\n\n* Unable to comply with study procedures.\n* Medically inappropriate for study participation in the opinion of the investigator.",{"count":296,"type":21},468,[298],"PHASE3","This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to \\\u003C18 years with ADHD.",[25],[302,25,303,304,305,306,307],"Attention deficit hyperactivity disorder","Sunosi","Solriamfetol","Axsome","Non-stimulant therapy","Dopamine norepinephrine reuptake inhibitor","2026-07-16",{"date":310,"type":36},"2026-07-21",{"date":312,"type":36},"2026-06-25",{"date":314,"type":21},"2028-06-30",{"name":316,"class":317},"Axsome Therapeutics, Inc.","INDUSTRY",9,{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":16,"minAge":326,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":56,"phases":329,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":337,"locationsCount":318},"100648122","phase-3-a-study-to-assess-the-efficacy-and-safety-of-solriamfetol-in-children-with-adhd-100648122","NCT07717879","A Study to Assess the Efficacy and Safety of Solriamfetol in Children With ADHD","A Phase 3, Randomized, 6-Week, Double-blind, Placebo-controlled Trial of Solriamfetol in Children Aged 6 to \u003C12 Years With Attention Deficit Hyperactivity Disorder (ADHD)","Inclusion Criteria:\n\n* Male or female, aged 6 to \\\u003C12 years.\n* Primary diagnosis of ADHD according to DSM-5 criteria.\n* Has parents\u002Flegal guardians provide written informed consent and has child provide written informed assent to participate in the study before the conduct of any study procedures.\n\nExclusion Criteria:\n\n* Unable to comply with study procedures.\n* Medically inappropriate for study participation in the opinion of the investigator.","6 Years","11 Years",{"count":296,"type":21},[298],"This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to \\\u003C12 years with ADHD.",[25],[302,25,303,304,305,306,307],{"date":310,"type":36},{"date":335,"type":36},"2026-07-06",{"date":314,"type":21},{"name":316,"class":317},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":16,"minAge":192,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":56,"phases":348,"briefSummary":349,"conditions":350,"keywords":353,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":4},"100648059","adhd-gut-problems-and-synbiotic-100648059","NCT07717359","ADHD, Gut Problems and Synbiotic","Gut-Brain Study: ADHD, Gastrointestinal Problems and Synbiotic Cap","Inclusion Criteria:\n\n* ADHD-diagnosis\n* Self-described gastrointestinal problems\n* Has not previously consumed Synbiotics\n* Be prepared to avoid supplements with lactic acid bacteria, calcium and vitamin B6, B9, and B12, starting from washout\n\nExclusion Criteria:\n\n* Has consumed antibiotics within the previous 6 weeks\n* Has a serious disease that requires treatment and\u002For leads to a weakened immune system","64 Years",{"count":347,"type":21},174,[58],"The scope of this study is to evaluate the impact of a synbiotic product (a combination of probiotic bacteria and prebiotics) on symptoms reported by participants with ADHD. The main focus is to study the efficacy of the synbiotic product as compared to a placebo in improving emotion regulation and gut-health associated symptoms in adults with ADHD.",[25,351,352],"Gastrointestinal","Emotion Regulation Abilities",[354,355,356,357,358,25],"emotion regulation","gastrointestinal health","probiotics","synbiotics","gut-brain axis",{"date":310,"type":36},{"date":361,"type":21},"2026-09",{"date":363,"type":21},"2027-12",{"name":365,"class":317},"Super Synbiotics AB",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":16,"minAge":192,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":56,"phases":376,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":44},"100537963","the-effect-of-a-brief-educational-intervention-for-adults-with-adhd-100537963","NCT06284655","The Effect of a Brief Educational Intervention for Adults With ADHD","The Effect of a Brief Educational Intervention for Adults With ADHD: a Randomized Control Trial","Inclusion Criteria:\n\n* Confirmed ADHD-diagnosis\n* Speaking a Scandinavian language\n* Willing to participate\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* In-patient on a acute psychiatric ward\n* Severe learning difficulties\n* Involvement in other research studies","65 Years",{"count":375,"type":21},60,[58],"This RCT-study proposes the evaluation of an intensive educational intervention tailored for adults with Attention Deficit Hyperactivity Disorder (ADHD) in community mental health centers (CMHCs). Given the prevalent challenges of prolonged waiting lists and low patient engagement in CMHCs, the research seeks to assess the efficacy of this intervention in enhancing patient engagement, self-efficacy, satisfaction with the information and overall health outcomes. The intervention, developed collaboratively with user representatives, combines a brief group-based educational sessions with standard clinical care. The primary hypotheses posit that this approach will lead to increased patient satisfaction with the treatment, patient self-efficacy, and activation compared to conventional treatment. Additionally, it aims to improve patients' satisfaction with information received. The study will employ a ITT analysis to assess the intervention's effects against usual treatment practices in outpatient settings. The anticipated outcome is a significant improvement in level of patient satisfaction, level of self-efficacy and level of satisfaction with the received information for patients with ADHD, potentially informing clinical practices and optimizing care for adults with ADHD.",[25],[25,380,381,382,383,384,385,386,387],"patient education","psychoeducation","patients' satisfaction","general self-efficacy","self-management","self-management skills","group-based education","peer co-led",{"date":389,"type":36},"2026-07-20",{"date":391,"type":36},"2025-02-14",{"date":393,"type":21},"2030-12",{"name":395,"class":71},"St. Olavs Hospital",{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":16,"minAge":192,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":56,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":44},"100402923","fidgeting-and-attentional-and-emotional-regulation-in-adhd-100402923","NCT04526600","Fidgeting and Attentional and Emotional Regulation in ADHD","Can Fidgeting Lead to Enhanced Attention and Emotional Regulation in ADHD?","Inclusion Criteria:\n\n* ADHD\n* History of fidgeting\n\nExclusion Criteria:\n\n* Currently taking psychoactive medication, with the exception of stimulant medication for ADHD or medication that can affect heart rate;\n* Presence of significant depression or psychotic disorders, autism, visual or hearing impairment or any other disorder that may interfere with task performance; and IQ below 85","30 Years",{"count":405,"type":21},109,[58],"This project will study how fidgeting relates to cognitive and emotional functioning in adults with attention-deficit\u002Fhyperactivity disorder (ADHD). It will determine, in a laboratory setting, whether movement and access to a \"fidget device\" providing sensory and motor stimulation can improve cognitive and emotional regulation (including on physiological measures) in adult ADHD. The investigators will also acquire pilot data for machine learning analyses to be used in future, large scale studies to identify gestures and touch characteristics associated with improved cognitive and emotional regulation to see if the data can predict and subsequently develop recommendations to improve performance and emotional control in natural settings (e.g., home, office, college classroom) for adult ADHD.",[25],"2026-07-01",{"date":335,"type":36},{"date":412,"type":36},"2022-03-21",{"date":414,"type":21},"2026-09-01",{"name":250,"class":71},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":16,"minAge":326,"maxAge":18,"enrollmentInfo":424,"targetDuration":4,"studyType":56,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":447,"locationsCount":44},"100645132","phase-3-a-phase-3-study-of-viloxazine-er-capsules-in-korean-children-and-adolescents-with-adhd-100645132","NCT07678827","A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Bridging Clinical Trial to Evaluate the Efficacy and Safety of Viloxazine Extended-Release (ER) Capsules (AK-D101) in Korean Children and Adolescents (6-17 Years of Age) With Attention-Deficit\u002FHyperactivity Disorder (ADHD)","AK-D101_BS","Inclusion Criteria\n\n1. Korean male or female subjects who are ≥6 and ≤17 years of age at the time of written informed consent.\n2. Subjects with a primary diagnosis of Attention-Deficit\u002FHyperactivity Disorder (ADHD) according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), confirmed by the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) at Visit 1 (Screening).\n3. Subjects with a Korean ADHD Rating Scale, 5th Edition (K-ARS-5) Total Score of ≥28 at Visit 1 (Screening) and Visit 2 (Baseline).\n4. Subjects with a Clinical Global Impression-Severity (CGI-S) score of ≥4 at Visit 1 (Screening) and Visit 2 (Baseline).\n5. Subjects who meet the following body weight criteria at Visit 1 (Screening):\n\n   * 6 to 11 years of age: ≥20 kg.\n   * 12 to 17 years of age: ≥35 kg.\n6. Subjects who agree not to initiate or take any ADHD medication other than the investigational medicinal product during the study. Subjects who are taking ADHD medication at Visit 1 (Screening) but whose ADHD symptoms are not adequately controlled with their current ADHD medication, as demonstrated by meeting Inclusion Criterion 3, may participate if they meet all other inclusion\u002Fexclusion criteria and have discontinued ADHD medication at least 7 days before Visit 2 (Baseline).\n7. Subjects considered suitable for participation in the clinical trial by the investigator based on clinical laboratory tests, vital signs, and ECG assessments, meeting all of the following criteria:\n\n   * Clinical laboratory tests: Results are within the normal range or, if outside the normal range, are not considered clinically significant. However, eGFR must be ≥30 mL\u002Fmin\u002F1.73 m², AST and ALT must be \\\u003C3 × upper limit of normal (ULN), and total bilirubin must be \\\u003C2 × ULN.\n   * Vital signs: Blood pressure, pulse rate, respiratory rate, and body temperature are within the normal range or, if outside the normal range, are not considered clinically significant.\n   * 12-lead ECG: No clinically significant abnormal findings.\n8. Subjects whose legally authorized representative(s), or parent(s), and the subject, as applicable, voluntarily agree to participate in this clinical trial and provide written informed consent\u002Fassent.\n\nExclusion Criteria:\n\n1. Subjects who are currently taking viloxazine, who previously took viloxazine for the treatment of ADHD but discontinued it due to adverse reactions or lack of efficacy, or who have a history of allergic reaction, hypersensitivity\\*, or intolerance to viloxazine extended-release capsules or any of their excipients.\n\n   \\*Hypersensitivity-related excipients: lactose, sucrose, Yellow No. 5 (Sunset Yellow FCF), and Yellow No. 203 (Quinoline Yellow WS).\n2. Subjects who, at Screening according to the MINI-KID, are diagnosed with a psychiatric disorder other than ADHD as the primary diagnosis, or who have a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator, may interfere with treatment adherence to the investigational medicinal product or affect study results. However, subjects with a history of Major Depressive Disorder may be eligible if no episode has occurred within 6 months prior to the Screening visit.\n3. Subjects with a history of diagnosis of significant central nervous system (CNS) disease or neuromuscular disease, including:\n\n   * CNS diseases, such as brain tumors, inflammatory CNS diseases, epilepsy, or cerebrovascular diseases.\n   * Neuromuscular diseases with childhood onset, such as Duchenne muscular dystrophy or myasthenia gravis.\n   * History of seizures, seizure-like symptoms, such as syncope, myoclonus, or severe muscle spasms, family history of seizure disorders in first-degree relatives, parents or siblings, and\u002For febrile convulsions.\n   * Other CNS or neuromuscular diseases that, in the investigator's medical judgment, may affect participation in the clinical trial.\n4. Subjects with a history of diagnosis of medically significant systemic disease.\n5. Subjects with a history of suicidal plan\u002Fintent, suicidal ideation, or one or more suicide attempts within 6 months prior to the Screening visit.\n6. Subjects whose BMI exceeds the 95th percentile for age and sex at the Screening visit.\n7. Subjects who have taken any of the following medications within the specified period prior to the first dose of investigational medicinal product at Visit 2 (Baseline):\n\n   * Monoamine oxidase inhibitors (MAOIs) within 14 days prior to the randomization visit.\n   * CYP1A2 substrate drugs, such as theophylline, melatonin, olanzapine, or duloxetine, within 7 days prior to the randomization visit.\n8. Pregnant or breastfeeding females, or females of childbearing potential, defined as those with confirmed menarche, with a positive pregnancy test result at the Baseline visit.\n9. Females of childbearing potential, defined as those with confirmed menarche, who do not agree to use adequate contraception during the study period and for 4 weeks after the last dose of the investigational medicinal product.\n\n   (\\*) Adequate contraception includes sexual abstinence, hormonal contraceptives without known drug interactions, intrauterine hormone-releasing systems, such as a levonorgestrel intrauterine system (IUS), intrauterine devices (IUDs), and surgical sterilization, including bilateral tubal ligation, salpingectomy, and vasectomy. However, periodic abstinence methods, such as calendar, symptothermal, or post-ovulation methods, use of spermicides alone, lactational amenorrhea method, double barrier methods, simultaneous use of female and male condoms, and withdrawal are not considered acceptable contraception.\n10. Subjects with food allergies, intolerances, dietary restrictions, or special diets that, in the investigator's judgment, may make the subject unsuitable for participation in this clinical trial.\n11. Subjects who have received or used any other investigational medicinal product or medical device within 30 days prior to Visit 1 (Screening).\n12. Subjects who are otherwise considered by the investigator to be unsuitable for participation in this clinical trial.",{"count":425,"type":21},156,[298],"This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter bridging clinical trial designed to evaluate the efficacy and safety of viloxazine extended-release capsules (AK-D101) compared with placebo in Korean children and adolescents aged 6 to 17 years with attention-deficit\u002Fhyperactivity disorder (ADHD). Eligible participants will be randomized in a 1:1 ratio to receive AK-D101 or placebo once daily for 8 weeks. Randomization will be stratified by study site and age group (children aged 6 to 11 years and adolescents aged 12 to 17 years). The primary efficacy endpoint is the change from baseline to Week 8, End of Treatment, in the Korean ADHD Rating Scale, 5th Edition (K-ARS-5) Total Score.",[209,429,25],"Attention-Deficit \u002F Hyperactivity Disorder",[25,431,432,433,434,435,436,437,438,439,440],"Attention-Deficit\u002FHyperactivity Disorder","Viloxazine","Viloxazine Extended-Release","Viloxazine ER","AK-D101","Qelbree","Korean Population","Bridging Study","Pediatric ADHD","Adolescent ADHD","2026-06-30",{"date":443,"type":36},"2026-07-02",{"date":445,"type":21},"2026-07",{"date":284,"type":21},{"name":448,"class":317},"Alvogen Korea",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":105,"sex":16,"minAge":326,"maxAge":231,"enrollmentInfo":456,"targetDuration":4,"studyType":56,"phases":458,"briefSummary":459,"conditions":460,"keywords":461,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":470,"leadSponsor":472,"locationsCount":4},"100646827","impact-of-the-mind-diet-on-adhd-symptoms-in-untreated-children-100646827","NCT07686458","Impact of the MIND Diet on ADHD Symptoms in Untreated Children","The Impact of the MIND Diet on ADHD Symptom Severity in Children With ADHD Not on Pharmacotherapy: A Randomized Controlled Trial in Lebanon","Inclusion Criteria:\n\n* Children aged 6 to 12 years at the time of enrollment\n* Clinical diagnosis of Attention-Deficit\u002FHyperactivity Disorder (ADHD) based on DSM-5 diagnostic criteria\n* Not currently receiving pharmacological treatment for ADHD\n* Child and caregiver willing to participate in the study procedures for the full 12-week intervention period\n\nExclusion Criteria:\n\nCurrent use of stimulant or non-stimulant pharmacological treatment for ADHD\n\n* Presence of medical conditions requiring specialized dietary restrictions (e.g., severe food allergies, metabolic disorders, or medically prescribed diets)\n* Severe neurological or developmental disorders that may interfere with participation or study assessments\n* Serious chronic medical illnesses that may affect growth, nutrition, or participation in dietary interventions\n* Inability of caregiver to comply with study procedures or dietary monitoring requirements",{"count":457,"type":21},158,[58],"This study, titled \"The Effect of the MIND Diet on ADHD Symptom Severity in Children with ADHD Not on Pharmacotherapy: A Randomized Controlled Trial in Lebanon,\" aims to evaluate whether a structured dietary intervention can improve behavioral and cognitive outcomes in children diagnosed with Attention-Deficit\u002FHyperactivity Disorder (ADHD). ADHD is one of the most common neurodevelopmental disorders in childhood and is characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with academic performance, social functioning, and daily activities. Although pharmacological treatments such as stimulant medications are considered the standard approach for ADHD management, many families either prefer to delay medication use or avoid it altogether due to concerns about side effects, stigma, or personal preferences. Consequently, there is growing interest in complementary and non-pharmacological approaches that may help manage symptoms and improve quality of life for children with ADHD.\n\nThe present study investigates the potential benefits of the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay), a dietary pattern that combines elements of the Mediterranean diet and the DASH diet. The MIND diet emphasizes foods associated with brain health and anti-inflammatory properties, including green leafy vegetables, berries, nuts, whole grains, olive oil, fish, legumes, and poultry, while limiting foods that may negatively affect cognitive function such as processed foods, fried foods, red meats, and sweets. Although the MIND diet has demonstrated neuroprotective effects in adults, particularly in relation to cognitive decline and neurodegenerative diseases, its potential role in managing ADHD symptoms in children remains largely unexplored. This study therefore seeks to address an important gap in the literature by evaluating whether dietary patterns that support brain health can influence behavioral and cognitive outcomes in pediatric ADHD.\n\nThe research employs a two-arm randomized controlled trial (RCT) design and will recruit a total of 158 children aged 6-12 years who have been diagnosed with ADHD and are not currently receiving pharmacological treatment. Participants will be randomly assigned in a 1:1 ratio to either the intervention group, which will follow the MIND diet, or a control group, which will receive general dietary advice based on standard nutritional recommendations. The intervention will last for 12 weeks, with data collected at baseline and at monthly follow-up visits throughout the study. During the intervention, families in the MIND diet group will receive education sessions from a nutritionist, educational materials including recipes and meal plans, and biweekly phone calls to support adherence and address any difficulties in implementing the diet.\n\nThe primary outcome of the study is the change in ADHD symptom severity, measured using the ADHD Rating Scale-IV (ADHD-RS-IV), a validated instrument completed by both parents and teachers. Assessing symptoms from both home and school settings provides a comprehensive evaluation of behavioral changes over time. Secondary outcomes include measures of executive functioning, assessed using the Behavior Rating Inventory of Executive Function (BRIEF) and selected tasks from the Cambridge Neuropsychological Test Automated Battery (CANTAB). These tools allow the study to evaluate both subjective and objective aspects of cognitive functioning, including working memory, planning, and inhibitory control.\n\nAdditional outcomes include assessments of quality of life, physical health, and dietary adherence. Quality of life will be measured using the Pediatric Quality of Life Inventory (PedsQL), while broader emotional and behavioral functioning will be evaluated using the Strengths and Difficulties Questionnaire (SDQ). Anthropometric measurements such as height, weight, and body mass index (BMI) will be recorded throughout the study to assess potential physical health changes associated with the dietary intervention. Dietary adherence will be monitored using repeated dietary records and a sociodemographic and barriers questionnaire designed to identify factors influencing families' ability to follow the diet. These analyses will also explore predictors of adherence, including caregiver involvement, socioeconomic status, and the child's age.\n\nThe study is particularly relevant within the Lebanese and broader Middle East and North Africa (MENA) context, where stigma surrounding mental health and concerns about medication often contribute to underutilization of mental health services. By examining a culturally acceptable and accessible intervention based on widely available foods, the study aims to provide families with an alternative or complementary strategy for ADHD management.\n\nOverall, this research seeks to determine whether adherence to the MIND diet can reduce ADHD symptom severity, improve executive function",[25],[462,463,464,25,465],"Nutritional Psychiatry","Non Pharmacological Intervention","Nutritional Intervention","MIND Diet","2026-06-29",{"date":468,"type":36},"2026-07-07",{"date":179,"type":21},{"date":471,"type":21},"2029-08",{"name":473,"class":71},"American University of Beirut Medical Center",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":105,"sex":16,"minAge":481,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":56,"phases":485,"briefSummary":486,"conditions":487,"keywords":493,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":500,"leadSponsor":502,"locationsCount":44},"100638259","brief-intervention-addressing-stigma-among-parents-of-children-with-mental-health-problems-100638259","NCT07594730","Brief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems","RCT of Brief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems","Inclusion Criteria:\n\n* Self-identify as English Speaking\n* Live in the US\n* Ages 25-50\n* Have a child 6-18 years old with either depression, ADHD, or a substance use problem\n\nExclusion Criteria:\n\n* Do not speak English\n* Do not live in the US\n* \\\u003C25 or \\>50\n* Do not have a child between ages 6-18 with depression, ADHD, or a substance use problem","25 Years","50 Years",{"count":484,"type":21},1600,[58],"The goal of this study is to test the efficacy of brief video interventions parental internalized stigma and stigma-related outcomes (e.g., treatment intentions, caregiver burden, secrecy) among parents (ages 25-50) of children ages 6-18 with depression, ADHD, or substance use problems.\n\nTimely identification and treatment of mental health problems in youth is a public health priority. However, many youth do not receive treatment, and stigma has been identified as the primary barrier to help-seeking. Parents experience stigma related to their children having mental health problems, which has been associated with reduced help-seeking and increased parental distress. Prior experiments have found brief video-based interventions (BVIs), 1-2 minute videos similar to those viewed by youth on social media platforms, based on the principle of \"social contact\" with individuals affected by a stigmatized condition, effective in reducing mental health stigma and increasing help-seeking.\n\nIn this 4-arm RCT, the investigators will recruit parents aged 25-50 using an online crowdsourcing platform, to test the efficacy of BVIs featuring a personal parent narrative of their experience with their child's a) depression, b) ADHD, or c) substance use, or d) a control condition that provides general written psychoeducational information without social contact.",[488,25,489,490,491,492],"Depression Disorders","Substance Abuse","Social Stigma","Help-Seeking Behavior","Caregiver Burden",[494,495,496],"social stigma","help-seeking behavior","caregiver burden","2026-06-26",{"date":441,"type":36},{"date":335,"type":21},{"date":501,"type":21},"2026-09-06",{"name":503,"class":71},"New York State Psychiatric Institute",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":16,"minAge":511,"maxAge":327,"enrollmentInfo":512,"targetDuration":4,"studyType":56,"phases":514,"briefSummary":516,"conditions":517,"keywords":518,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":44},"100641724","phase-4-eeg-biomarkers-for-adhd-stimulant-treatment-100641724","NCT07650643","EEG Biomarkers for ADHD Stimulant Treatment","EEG Biomarkers for Pediatric ADHD Treatment Stratification","Inclusion Criteria:\n\n1. Ages 7:0 - 10:11 (years:months)\n2. Has a diagnosis of ADHD or being evaluated for ADHD\n3. Stimulant naïve or previously trialed stimulant medications for \\\u003C 6 months without achieving symptom remission, per caregiver report and\u002For medical chart review (if available)\n4. CGI-Severity rating of 4 \"Moderately ill\" through 6 \"Severely ill.\"\n5. Willing and able to comply with study procedures\n\nExclusion Criteria:\n\n1. Use of stimulants or other psychotropic medications within 7 days before Eligibility Visit\n2. History of severe side effects to stimulants (suicidality, complete loss of appetite, cardiopulmonary complications) per caregiver report or medical chart review, determined by the study MD\n3. Intellectual disability or IQ \\\u003C 75 per medical chart review or performance on standardized cognitive testing during the Eligibility Visit\n4. Diagnosis of Autism spectrum disorder (ASD) per medical chart review or caregiver report\n5. Fetal alcohol exposure per medical chart review or caregiver report\n6. Current suicidal ideation per caregiver or child report on CSSRS\n7. Non-febrile seizures per caregiver report or medical chart review\n8. Cardiopulmonary conditions, pregnancy or other medical conditions that contraindicate psychostimulant use per determination by the study MD","7 Years",{"count":513,"type":21},220,[515],"PHASE4","Pediatric attention deficit hyperactivity disorder (ADHD) affects up to 10% of children in the U.S. and more than 90% are prescribed stimulant medications according to clinical guidelines. The standard of care for pharmacological treatment of ADHD is a \"trial-and-error\" approach that requires frequent dose adjustments, side effects management, and communication among doctors, parents, and school personnel over weeks, months, and years. In the first year following prescription of stimulant medications, \\>50% of doctors are not able to conduct the recommended follow-up with their patients. Many patients stop taking medications or keep taking medications that do not work well, as a result.\n\nThis investigation will use a non-invasive brain imaging technique called EEG to look for activity in the brain that can predict which children with ADHD will respond well to two commonly prescribed stimulant medication groups, methylphenidate and amphetamines. Based on a previous study, it is expected that EEG signals can differentiate among children whose ADHD symptoms will get better on methylphenidate, and those whose ADHD symptoms will get better on amphetamines.\n\n220 participants ages 7-11 with ADHD will be enrolled. Participants will not have autism or intellectual disabiltiy. They will not currently be taking psychiatric medications. Participants will not have not taken stimulant medications before or have tried stimulant medications \\>6 months or experienced an improvement in their ADHD symptoms by taking a stimulant medication before.\n\nStudy Participation Includes:\n\n1. Participant and caregiver complete a 3-hour visit at the Arnett Laboratory at 2 Brookline Place. During this visit, participants complete a brief IQ test and an EEG while their caregiver completes questionnaires and a clinical interview. The caregiver will give permission to request survey responses from the participant's teacher.\n2. The next day, the participant and caregiver will come back to the laboratory for a 1-hour visit. The participant will do another EEG while the caregiver fills out more surveys. The doctor will take the participant's vital signs and prescribe the medication.\n3. The participant will be randomly assigned to take either methylphenidate HCl or amphetamines every morning for 3 weeks. At the end of each week, the caregiver and teacher will fill out a questionnaire about the participant's behaviors and symptoms, including side effects.\n4. For one week, the participant will not take medications. They will come back into the lab for another EEG at the end of that week.\n5. The participant will then take the other medication every morning for 3 weeks. At the end of each week, the caregiver and teacher will fill out a questionnaire about the participant's behaviors and symptoms, including side effects.\n6. It will take participants about 7 weeks to complete this study. During this time, they will complete 3 in-person and 6 virtual study visits.\n7. The research funds will cover cost associated with the study. The participant's health insurer will not be billed for the medications or treatment. Medications will be provided through the research pharmacy.\n8. Participants will be given a report at the end of the study with details about the medication trials, symptom response, and any other findings. They will receive up to $270 for the completion of the study. Some travel-related costs will be covered by the study.",[25],[519,29,520,521,25,522,523],"stimulants","biomarker","randomized crossover","treatment","stratification","2026-06-12",{"date":526,"type":36},"2026-06-16",{"date":528,"type":21},"2026-09-15",{"date":530,"type":21},"2031-08-31",{"name":532,"class":71},"Boston Children's Hospital",{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":16,"minAge":231,"maxAge":192,"enrollmentInfo":541,"targetDuration":4,"studyType":56,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":557,"locationsCount":44},"100541508","trauma-adapted-yoga-in-child--adolescent-psychiatry-100541508","NCT06330779","Trauma-adapted Yoga in Child & Adolescent Psychiatry.","Trauma-adapted Yoga in Child & Adolescent Psychiatry: A Multicenter Study.","TAY-CAP","Inclusion Criteria:\n\n* Adolescents who have received a diagnosis (not under evaluation) of PTSD and\u002For ADHD\n* Understanding English or Swedish languages.\n\nExclusion Criteria:\n\n* Ongoing substance use,\n* active manic periods,\n* psychotic disorders,\n* suicidality,\n* cognitive impairment.\n* serious physical illness prohibiting participation in physical activities.",{"count":542,"type":21},180,[58],"The goal of this randomized clinical trial is to evaluate the efficacy of trauma-adapted yoga as a complementary intervention to care as usual in child and adolescents psychiatry clinics, in the population of adolescents with the diagnosis of ADHD and\u002For PTSD. We hypothesize that trauma-adapted yoga (TAY) is an effective non-pharmacological intervention for adolescent with ADHD and\u002For PTSD. Aims: (1) Validate the impact of TAY on the mental health \\& quality of life of adolescents with ADHD and\u002For PTSD. (2) Investigate the feasibility of online TAY for continued self-care. (3) Explore adolescents' experiences \\& parental perspectives on TAY in their treatment. (4) Explore healthcare professionals' experience on the integration of TAY into clinical practice.\n\nWithin and between group (yoga group vs waiting list) analyses will be performed.",[25,546,547,548,549,550],"PTSD","Quality of Life","Self-Control","Pain","Affect","2026-05-15",{"date":553,"type":36},"2026-05-19",{"date":555,"type":36},"2025-02-01",{"date":181,"type":21},{"name":558,"class":71},"University West, Sweden",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":105,"sex":567,"minAge":17,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":570,"conditions":571,"keywords":572,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":44},"100637323","investigating-health-equity-and-resilience-in-girls-and-women-with-adhd-across-the-lifespan-100637323","NCT07597707","Investigating Health, Equity, and Resilience in Girls and Women With ADHD Across the Lifespan","ADHD-Her: An Observational Research Protocol for Investigating Health, Equity, and Resilience (HER) in Girls and Women With ADHD Across the Lifespan","ADHD-Her","Inclusion Criteria:\n\n* Assigned female at birth or identify as girl or women\n* Fluency in English or French\n* Aged 10 years or older\n* Currently reside in Canada\n* Access to technology to complete study measures\n\nExclusion Criteria:\n\n* Self-reported intellectual disability","FEMALE",{"count":569,"type":21},1460,"The goal of this observational study is to generate a comprehensive, multi-dimensional dataset of health indicators collected from girls and women (aged 10 years and older) with and without ADHD across the lifespan. Participants will be asked to complete a detailed survey about hormonal and developmental life phases, ADHD status and symptoms, childhood experiences, health and well-being, and psychosocial outcomes.",[25],[25,573,574,575,576,577,578,579,580,581],"women","woman","girl","girls","female","females","hormone","hormones","hormonal","2026-05-13",{"date":553,"type":36},{"date":585,"type":36},"2025-08-25",{"date":587,"type":21},"2026-12-31",{"name":221,"class":71},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":16,"minAge":326,"maxAge":53,"enrollmentInfo":595,"targetDuration":4,"studyType":56,"phases":597,"briefSummary":598,"conditions":599,"keywords":604,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":612,"locationsCount":614},"100640267","intensive-neurofeedback-protocol-for-children-with-adhd-a-proof-of-concept-study-comparing-iapf-personalized-and-standard-theta-beta-ratio-training-100640267","NCT07595783","Intensive-neurofeedback Protocol for Children With ADHD: A Proof-of-concept Study Comparing iAPF-personalized and Standard Theta-beta-ratio Training","Inclusion Criteria:\n\n* Children aged 6-13 years. Confirmed ADHD diagnosis (ICD 10: F90.0, F90.1, or F98.8)\n* German-speaking children with normal or corrected vision.\n\nExclusion Criteria:\n\n* Children with neurological disorders (e.g., Epilepsy)\n* Children without an ADHD diagnosis\n* Caregivers with inability to provide informed consent or complete questionnaires\n* Participation in neurofeedback that was conducted in the year prior to the intended participation or is still ongoing.\n\nThe intake of medication or psychotherapeutic treatments and ICD-10 diagnosis are queried at T1, T2 and T3. These are recorded as control variables and are not exclusion criteria. The medication intake was kept constant during the NF training.",{"count":596,"type":21},40,[58],"The first aim of this clinical trial is to test the feasibility and signal validity of a new approach to neurofeedback training (NF) using intensive EEG-based theta-beta NF for children with ADHD in the context of NF camps during school holidays. The second aim is to compare the efficacy of two neurofeedback protocols in reducing ADHD symptoms. Previous study results highlight that children with ADHD frequently show increased Theta-Beta-Ratios (TBR) in the qEEG, probably associated with attention difficulties, which may be ameliorated following neurofeedback training. However, the current state of research shows heterogenous findings regarding the efficacy of standard TBR NF for children with ADHD. Further study results suggest that personalized NF training protocols, based on the individual alpha peak frequency (iAPF), may be more effective in reducing ADHD symptoms than standardized ones.\n\nTherefore, in this proof-of-concept study of children with ADHD a standard TBR NF protocol is compared with an iAPF-personalized TBR NF (iAPF-TBR NF) protocol (based on the previously obtained iAPF). The study is designed as a randomized controlled intervention trial (RCT) with three assessment points (pre \\[T1\\], post \\[T2\\] and 6-month follow-up \\[T3\\]). Primary endpoints include the reduction of ADHD symptoms assessed by parent-, teacher- and self-report questionnaires. Furthermore, it is hypothesized that NF training is associated with better performance in a sustained attention and executive function test and a reduced TBR in qEEG, particularly following iAPF-TBR NF.\n\nThe main questions are:\n\n* Is it feasible to train groups of up to 12 children with two sessions NF per day for an eight-day-period during their school holidays?\n* Does iAPF-TBR NF provide a valid neuromodulatory signal compared to the standard-TBR-NF protocol? Do the frequency boundaries demonstrate spectral stability across the 16 training sessions?\n* Does the personalized iAPF-TBR NF training reduce ADHD symptoms measured immediately after the training more than standard-TBR-NF training? (comparison T2-T1)\n* Does the personalized iAPF-TBR NF training reduce ADHD symptoms measured 6 months after the NF training more than standard TBR-NF training? (comparison T3-T1)\n* Does the reduction in ADHD symptoms measured immediately after the NF-training persist until the 6-month follow-up? Do possible differences between iAPF-TBR NF training and standard TBR NF training remain? (comparison T3-T2)\n\nPost-hoc analyses of the courses are carried out. In addition, selectivity analyses will be carried out for clinical subgroups (e.g. different ADHD profiles)",[25,600,601,602,603],"Inattention","Hyperactivity","Impulsivity","Executive Dysfunction",[605,25,606],"EEG-neurofeedback","children","2026-05-12",{"date":553,"type":36},{"date":610,"type":36},"2024-07-09",{"date":587,"type":21},{"name":613,"class":71},"Bielefeld University",2,{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":16,"minAge":623,"maxAge":481,"enrollmentInfo":624,"targetDuration":4,"studyType":56,"phases":625,"briefSummary":626,"conditions":627,"keywords":628,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":44},"100631701","adhdme-targeting-self-esteem-in-youth-with-adhd-100631701","NCT07504107","ADHD&me: Targeting Self-esteem in Youth With ADHD","ADHD&me: a Randomized Controlled Trial to Target Self-esteem in Youth With ADHD","ADHD&me","Inclusion Criteria:\n\n* 16-25 years old.\n* Official ADHD diagnosis, that is confirmed by research team using the clinical interview MINI-S.\n* Low self-esteem, determined through a structured and multi-step procedure to minimize subjectivity:\n\n  * Referral by clinician. Clinicians from participating institutions identify potential participants. To ensure a uniform understanding of the study population and inclusion criteria, all clinicians receive specific training. The researcher(s) conduction the baseline assessment are also familiar with these training materials, so that the inclusion procedure is applied consistently.\n  * Telephone screening. Two items from the Rosenberg Self-Esteem Scale (RSES; Rosenberg, 1965) are administered (\"At times I think I am no good at all\" and \"All in all, I am inclined to think I am a failure\"). A score of 3 (agree) or 4 (strongly agree) on either of these items is considered indicative of low self-esteem.\n  * Baseline confirmation. During the baseline measurement, the full Rosenberg Self-Esteem Scale is administered. A cutoff score of \\\u003C 15 is used as an objective reference point. This score is combined with a standardized clinical interview conducted by a trained researcher psychologist. At the ADHD section of the MINI-S at the baseline measurement, participants are asked by the researcher psychologist how their symptoms interfere with domains such as work, study, relationships, and self-esteem. If self-esteem is not mentioned, a follow-up question will be asked: \"Many people with ADHD feel their symptoms affect their self-esteem, for example due to repeated negative feed- back, feeling like they are not good at things, or failing short. Do you recognize this in yourself\"? Based on the participant's response, the trained researcher psychologist interviewer forms a professional, clinical impression of whether there are indicators of persistently low self-esteem (i.e.,insecurity, fear of failure, strong reactions to criticism, perfectionism, distress related to ADHD symptoms). This clinical assessment approach is based on examples provided by the Diagnostic Interview for ADHD in Adults (DIVA-2-NL; Kooij \\& Francken, 2010). In all doubtful cases, the inclusion decision will be discussed in consensus meetings with the research team and supervisor, ensuring high inter-rater reliability.\n* Pharmacological treatment for ADHD is allowed, but medication dose should be stabilized for a minimum of 4 weeks at baseline measurement (T0). Although changes in ADHD medication during the study are not preferred, they may occur in practice. Any such changed will be carefully documented.\n\nExclusion Criteria:\n\n* Concurrent psychopathology that requires immediate attention (e.g., severe depression, suicidal thoughts\u002Frisk of suicide (as determined by the referring therapist and\u002For research team). Other comorbidity is allowed.\n* Undergoing any concurrent psychological treatment during the study, including any form of therapy for ADHD (e.g., CBT for planning skills). Psychoeducation completed prior to the study entry is allowed, but not during the study.\n* Low self-esteem that directly stems from a traumatic experience, which would indicate the need for trauma-specific treatment. This will be determined by the referring therapist. If someone in addition suffers from low self-esteem due to the ADHD symptoms, an appropriate timing of each treatment will be dis- cussed by the referring therapist and potential client.\n* IQ \\\u003C 80 assessed with two WAIS-IV subscales (Wechsler, 2008): Vocabulary and Block Design.\n* Severe substance use (as determined by the referring therapist and\u002For research team).\n* Confirmed Autism Spectrum Disorder (ASD) diagnosis. This also applies when the referring therapist indicates that an ASD diagnosis is very likely, even if it has not yet been established. Since ASD diagnostic procedures are time-consuming and fall outside the scope of this research project, formal ASD assessment will not be conducted within this study.\n\nNote. If included participants receive unforeseen supportive sessions outside the research setting, or if unforeseen medication changes occur during the study, these will be documented and considered during the analysis.","16 Years",{"count":20,"type":21},[58],"The goal of this clinical trial is to learn whether the ADHD\\&me (ADHD\\&ik) intervention can improve self-esteem in youth aged 16-25 years with Attention Deficit Hyperactivity Disorder (ADHD). The ADHD\\&me program is a cognitive behavioral therapy (CBT)-based intervention designed to help people with ADHD to develop a more positive view of themselves in their transition to adulthood.\n\nThe main questions it aims to answer are:\n\n* Does the ADHD\\&me intervention improve self-esteem in youth with ADHD, and are these effects maintained over time?\n* Does the intervention also improve related outcomes, such as masking of ADHD-related behaviors and co-occurring mental health symptoms including anxiety, depression, and stress?\n\nIn this RCT, participants are assigned either to immediate treatment or to a waitlist control condition, with the latter receiving the intervention after an eight-week delay.\n\nParticipants will:\n\n* Take part in seven individual therapy sessions according to the ADHD\\&me intervention.\n* Complete questionnaires about self-esteem, masking of ADHD-related behaviors, ADHD symptoms, and co-ccurring mental health symptoms at several time points.\n* Complete short daily assessments (ecological momentary assessment) during one week at the start of the study and one week after the intervention or waitlist period to report momentary self-esteem, emotions, distress, and activities.",[25],[25,629,630,631,632,633,634,635,636],"Self-esteem","Masking","Comorbidity","Young adults","Youth","CBT","Intervention","RCT","2026-05-11",{"date":639,"type":36},"2026-05-14",{"date":641,"type":36},"2026-03-25",{"date":643,"type":21},"2028-03-31",{"name":645,"class":71},"Universiteit Leiden",{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":105,"sex":16,"minAge":192,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":56,"phases":656,"briefSummary":657,"conditions":658,"keywords":661,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":673,"locationsCount":44},"100596199","testing-a-measurement-feedback-app-to-improve-data-quality-supervision--outcomes-in-behavioral-health-100596199","NCT07042347","Testing a Measurement Feedback App to Improve Data Quality, Supervision & Outcomes in Behavioral Health","RCT of a Measurement Feedback App to Improve Data Quality, Supervision & Outcomes in Behavioral Health","Footsteps","Inclusion Criteria:\n\n* Aides must be working with at least one client in school who meets the following criteria: 1) between 3-17 years, 2) has a diagnosis associated with a challenging behavior (e.g., autism spectrum disorder, attention deficit hyperactivity disorder, oppositional defiant disorder) as indicated on their treatment plan, and 3) receiving 1:1 aide support.\n* Supervisors must be employed by a community behavior health agency and supervise a participating aide. The investigators will recruit supervisors in dyads and not triads (i.e., no supervisors with two \\[or more\\] aides) to ensure there are 30 supervisor-aide dyads in total).\n\nExclusion Criteria:\n\n* Aides who participated in the pilot trial of the Footsteps will be excluded from participating to recruit a sample naïve to Footsteps and the control app.",{"count":655,"type":21},200,[58],"The goal of this clinical trial is to test whether a smartphone-based data collection and feedback application (\"Footsteps\") improves the quality of behavioral data collected by one-to-one aides and leads to better youth mental health outcomes in school-aged youth (ages 4-17) who receive one-to-one support in schools.\n\nThe main questions it aims to answer are:\n\n1. Does the Footsteps app improve aides' data collection quality (i.e., consistency, timeliness, and completeness)?\n2. Does Footsteps use lead to improved youth behavioral health outcomes (e.g., SDQ, YTP scores)?\n3. Does Footsteps improve communication and supervision processes between aides and clinical supervisors?\n\nResearchers will compare aides using Footsteps to those using a \"data collection only\" control app to see if Footsteps leads to higher quality data collection, enhanced supervisory communication, and better youth outcomes.\n\nParticipants will:\n\n* Use either Footsteps or a control app to record de-identified data on one client's behaviors and skills over 12 weeks\n* Complete biweekly online surveys about data collection experiences, youth progress, and aide-supervisor communication\n* Participate in a virtual intake and post-trial meeting\n* (For a subset) Participate in a 30-45 minute qualitative interview about their experience using the app",[115,659,25,660],"Challenging Behavior","Oppositional Defiant Disorder",[662,663,664,665,666],"data collection","Behavioral Health Technician (BHT)","behavioral economics","implementation science","supervisory processes","2026-05-07",{"date":669,"type":36},"2026-05-08",{"date":671,"type":36},"2026-04-08",{"date":314,"type":21},{"name":674,"class":71},"University of Pennsylvania",{"id":676,"slug":677,"hasResults":12,"nctId":678,"briefTitle":679,"officialTitle":680,"acronym":681,"eligibilityCriteria":682,"healthyVolunteers":12,"sex":567,"minAge":192,"maxAge":4,"enrollmentInfo":683,"targetDuration":4,"studyType":56,"phases":685,"briefSummary":686,"conditions":687,"keywords":690,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":698,"completionDateStruct":700,"leadSponsor":702,"locationsCount":44},"100593042","expectant-moms-managing-attention-deficit-hyperactivity-disorder-100593042","NCT07001293","Expectant Moms Managing Attention-Deficit\u002F Hyperactivity Disorder","Supporting Expectant Mothers With ADHD Through the Transition to Parenthood: A Pilot RCT","MomMA","Inclusion Criteria:\n\n1. meets full DSM-5 criteria for ADHD\n2. is between 14- and 22-weeks of gestation\n3. 18 years of age or older\n4. English speaking\n5. Lives in Pennsylvania\n\nExclusion Criteria:\n\n1. substance use disorders requiring dual diagnosis treatment\n2. intellectual disability\n3. bipolar disorder, psychosis, and major depressive disorder with suicidal ideation\n4. the following high complexity medical conditions during pregnancy: maternal cancer, multiples, placenta accreta, and\u002For fetus known to have a severe congenital condition",{"count":684,"type":21},80,[58],"The goal of this study is to test a behavioral program for pregnant individuals with ADHD. This behavioral program focuses on skills for managing ADHD and related symptoms in pregnancy and postpartum.\n\nThis pilot effectiveness-implementation trial aims to (1) preliminarily evaluate the MomMA behavioral intervention compared to treatment as usual (TAU) on clinical outcomes and (2) evaluate implementation outcomes, including feasibility and acceptability of clinic screening within existing OB workflows; assessment and intervention protocols; provider training\u002Ffidelity to manual; and all other study protocols from the perspective of real-world providers and participants.",[25,688,689],"Perinatal","Behavioral Intervention",[25,691,692,689,693,694,695],"Pregnancy","Perinatal Mental Health","Parenting","Emotion Regulation","Executive Functioning","2026-05-05",{"date":667,"type":36},{"date":699,"type":36},"2026-04-26",{"date":701,"type":21},"2028-05-31",{"name":703,"class":71},"University of Pittsburgh",{"id":705,"slug":706,"hasResults":12,"nctId":707,"briefTitle":708,"officialTitle":709,"acronym":4,"eligibilityCriteria":710,"healthyVolunteers":12,"sex":16,"minAge":230,"maxAge":231,"enrollmentInfo":711,"targetDuration":4,"studyType":56,"phases":712,"briefSummary":713,"conditions":714,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":715,"startDateStruct":716,"completionDateStruct":718,"leadSponsor":720,"locationsCount":44},"100477089","central-executive-training-and-parent-training-for-adhd-100477089","NCT05492422","Central Executive Training and Parent Training for ADHD","Evaluating the Efficacy of Sequenced Central Executive and Behavioral Parent Training for Children With ADHD","Inclusion:\n\n1. Children ages 8-12 with principal ADHD diagnoses (via K-SADS); and\n2. parent AND teacher ratings in clinical\u002Fborderline range based on age and sex on ADHD Rating Scale (ADHD-5) or Behavior Assessment Scale for Children (BASC-3) Attention Problems\u002FHyperactivity subscales (i.e., 90th percentile or higher based on both informants).\n\nAll DSM-5 ADHD presentations will be eligible.\n\nExclusion:\n\n1. gross neurological, sensory, or motor impairment;\n2. history of seizure disorder, psychosis, bipolar, or severe dysregulation disorders that may interfere with participation (e.g., disruptive mood dysregulation, intermittent explosive, reactive attachment, substance use);\n3. intellectual disability or Wechsler Intelligence Scale for Children (WISC-V) short-form standard score \\\u003C70;\n4. conditions requiring acute intervention, e.g., active suicidality; and\n5. non-English speaking child or parent.",{"count":655,"type":21},[58],"The goal of the current project is to combine two evidence- based treatments for school-aged children with ADHD: Central Executive Training (CET) and Behavioral Parent Training (BPT). CET is a computerized training intervention that improves ADHD symptoms and academic functioning by improving children's working memory abilities. BPT is a therapeutic intervention that improves family functioning and child oppositional-defiant (ODD) symptoms by changing parenting behaviors. Their combined use is expected to provide complementary and additive benefits, particularly if CET is delivered before BPT.",[25],{"date":667,"type":36},{"date":717,"type":36},"2022-10-03",{"date":719,"type":21},"2027-08-01",{"name":721,"class":71},"Florida State University",{"id":723,"slug":724,"hasResults":12,"nctId":725,"briefTitle":726,"officialTitle":726,"acronym":727,"eligibilityCriteria":728,"healthyVolunteers":12,"sex":16,"minAge":326,"maxAge":729,"enrollmentInfo":730,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":732,"conditions":733,"keywords":734,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":738,"lastUpdatePostDateStruct":739,"startDateStruct":740,"completionDateStruct":742,"leadSponsor":744,"locationsCount":44},"100590762","advancing-identification-of-circadian-delay-in-adhd-youth-associations-with-clinical-heterogeneity-and-cognition-100590762","NCT06971640","Advancing Identification of Circadian Delay in ADHD Youth: Associations With Clinical Heterogeneity and Cognition","CIRCA","Inclusion Criteria:\n\n1. Child ages 6-9\n2. Meet criteria for a primary psychiatric diagnosis of DSM-5 ADHD, any presentation\n3. Intellectual functioning \\>80\n4. Healthy (i.e., no major medical problems)\n5. If applicable, willingness to suspend use of melatonin during the study period\n\nExclusion Criteria:\n\n1. Meet DSM-5 criteria for psychosis, bipolar, or autism spectrum disorders\n2. Diagnosis of occult sleep disorders, including sleep apnea or restless leg syndrome\n3. Medication for sleep other than melatonin\n4. Plans to initiate stimulant medication during the study period","9 Years",{"count":731,"type":21},250,"The purpose of this study is to better understand sleep and circadian functioning in children with ADHD using home-based measures, parent report, and a lab based melatonin assessment. Investigators will also examine how sleep relates to psychiatric health and cognition among children with ADHD. The investigator for this study is Dr. Jessica Lunsford-Avery from the Department of Psychiatry.",[116,25],[25,735,736,737],"attention deficit disorder with hyperactivity","circadian rhythm","dim light melatonin onset","2026-05-04",{"date":696,"type":36},{"date":741,"type":36},"2025-05-28",{"date":743,"type":21},"2029-11",{"name":745,"class":71},"Duke University",{"id":747,"slug":748,"hasResults":12,"nctId":749,"briefTitle":750,"officialTitle":751,"acronym":752,"eligibilityCriteria":753,"healthyVolunteers":12,"sex":16,"minAge":754,"maxAge":231,"enrollmentInfo":755,"targetDuration":4,"studyType":56,"phases":757,"briefSummary":758,"conditions":759,"keywords":760,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":762,"lastUpdatePostDateStruct":763,"startDateStruct":764,"completionDateStruct":766,"leadSponsor":768,"locationsCount":44},"100462296","impact-of-parental-emotion-regulation-on-the-treatment-of-adhd-100462296","NCT05299814","Impact of Parental Emotion Regulation on the Treatment of ADHD","The Impact of Parental Emotion Regulation Capacity on Behavioral Treatment for Pediatric ADHD","PERS","Inclusion Criteria:\n\n* Parent of a child ages 5-12 with ADHD\n* Parent must report that the child has at least a mild level of symptoms at home of Oppositional Defiant Disorder (ODD) on the Disruptive Behavior Disorder Rating Scale (DBDRS)\n\nExclusion Criteria:\n\n1. Not being the parent of a child ages 5-12 who meets diagnostic criteria for ADHD.\n2. Non English Speaking\n3. the child with ADHD has a diagnosis of intellectual delay or has prominent autistic traits\n4. Another child in the same family participating in this study already\n5. Parent does not have a smartphone or tablet device to complete EMA ratings or does not reside with child for the majority of the time.","5 Years",{"count":756,"type":21},65,[58],"Aim: To examine if parental emotion regulation (ER) moderates the response to parent training interventions.\n\nH1: Reduced parental ER capacity will predict diminished efficacy for behavioral parent training to improve negative parenting behavior (NPB) and behavior problems in offspring with ADHD.\n\nH2: Increased parental emotional reactivity will predict diminished efficacy for behavioral parent training to improve negative parenting behavior (NPB) and behavior problems in offspring with ADHD.",[25],[761],"oppositional behaviors, conduct problems","2026-05-01",{"date":667,"type":36},{"date":765,"type":36},"2017-04-13",{"date":767,"type":21},"2026-10-31",{"name":769,"class":71},"Milton S. Hershey Medical Center"]